Third Rock Ventures GP V, LP — SEC Form 4 filings
SEC reporting owner CIK 1977498. 11 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-06-10 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 3 filings — 1,709,203 shares, $17,980,525 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 7 legs across 5 filings — 1,001,908 shares, $41,791,084 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 426,005 shares @ $40.32 ($17,175,244) in Rapport Therapeutics, Inc., filed 2026-04-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | 10% owner | 5 | — | 5 legs · 854,708 sh · $34,391,226 | 5 |
| Septerna, Inc. (SEPN) | 10% owner | 4 | 5 legs · 1,709,203 sh · $17,980,525 | 2 legs · 147,200 sh · $7,399,858 | 4 |
| Maze Therapeutics, Inc. (MAZE) | 10% owner | 2 | — | — | 6 |
Form 4 filings — Third Rock Ventures GP V, LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Septerna, Inc. (SEPN) jointly with Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Sale (S): 147,059 @ $50.27 · Sale (S): 141 @ $51.08 | EDGAR |
| 2026-05-28 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Sale (S): 18,572 @ $40.05 | EDGAR |
| 2026-05-13 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Sale (S): 133,618 @ $40.24 | EDGAR |
| 2026-05-11 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Sale (S): 271,495 @ $40.12 · Sale (S): 5,018 @ $40.31 | EDGAR |
| 2026-04-21 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Sale (S): 426,005 @ $40.32 | EDGAR |
| 2025-11-05 | 4 | Maze Therapeutics, Inc. (MAZE) jointly with Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., TRV GP IV, LLC, Third Rock Ventures V, L.P., TRV GP V, LLC | Other (J): 1,600,000 | EDGAR |
| 2025-02-26 | 4 | Septerna, Inc. (SEPN) jointly with Third Rock Ventures VI, L.P., Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Purchase (P): 18,861 @ $6.00 | EDGAR |
| 2025-02-24 | 4 | Septerna, Inc. (SEPN) jointly with Third Rock Ventures VI, L.P., Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Purchase (P): 612,674 @ $5.92 · Purchase (P): 427,668 @ $5.94 | EDGAR |
| 2025-02-04 | 4 | Maze Therapeutics, Inc. (MAZE) jointly with Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., TRV GP IV, LLC, Third Rock Ventures V, L.P., TRV GP V, LLC | Conversion (C): 5,762,788 @ $0 · Conversion (C): 950,800 @ $0 · Conversion (C): 45,833,334 (derivative) @ $0 · Conversion (C): 9,725,709 (derivative) @ $0 · Conversion (C): 9,166,666 (derivative) @ $0 | EDGAR |
| 2024-10-28 | 4 | Septerna, Inc. (SEPN) jointly with Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Conversion (C): 4,790,773 @ $0 · Conversion (C): 2,872,956 @ $0 · Purchase (P): 370,500 @ $18 · Purchase (P): 279,500 @ $18 · Conversion (C): 41,250,000 (derivative) @ $0 · Conversion (C): 24,737,017 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with Third Rock Ventures V, L.P., TRV GP V, LLC, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., TRV GP VI, LLC | Conversion (C): 6,551,449 @ $0 · Conversion (C): 969,218 @ $0 · Conversion (C): 56,091,177 (derivative) @ $0 · Conversion (C): 8,000,000 (derivative) @ $0 · Conversion (C): 298,103 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1977498 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →